Cabaletta Bio Future Growth
Future criteria checks 0/6
Cabaletta Bio is forecast to grow earnings and revenue by 1.2% and 84.2% per annum respectively. EPS is expected to grow by 11.2% per annum. Return on equity is forecast to be -81.8% in 3 years.
Key information
1.2%
Earnings growth rate
11.2%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | 84.2% |
| Future return on equity | -81.8% |
| Analyst coverage | Good |
| Last updated | 06 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3 | -159 | -132 | -107 | 6 |
| 12/31/2025 | N/A | -135 | -113 | -103 | 7 |
| 12/31/2024 | N/A | -114 | -99 | -91 | 7 |
| 6/30/2024 | N/A | -90 | -76 | -74 | N/A |
| 3/31/2024 | N/A | -77 | -66 | -65 | N/A |
| 12/31/2023 | N/A | -68 | -54 | -54 | N/A |
| 9/30/2023 | N/A | -62 | -50 | -49 | N/A |
| 6/30/2023 | N/A | -57 | -48 | -47 | N/A |
| 3/31/2023 | N/A | -56 | -49 | -46 | N/A |
| 12/31/2022 | N/A | -53 | -49 | -46 | N/A |
| 9/30/2022 | N/A | -51 | -47 | -45 | N/A |
| 6/30/2022 | N/A | -51 | -45 | -43 | N/A |
| 3/31/2022 | N/A | -50 | -39 | -38 | N/A |
| 12/31/2021 | N/A | -46 | -35 | -34 | N/A |
| 9/30/2021 | N/A | -42 | -34 | -33 | N/A |
| 6/30/2021 | N/A | -39 | -30 | -29 | N/A |
| 3/31/2021 | N/A | -36 | -31 | -31 | N/A |
| 12/31/2020 | N/A | -33 | -27 | -27 | N/A |
| 9/30/2020 | N/A | -29 | -26 | -25 | N/A |
| 6/30/2020 | N/A | -26 | -23 | -23 | N/A |
| 3/31/2020 | N/A | -21 | -19 | -19 | N/A |
| 12/31/2019 | N/A | -22 | -17 | -16 | N/A |
| 9/30/2019 | N/A | -19 | -10 | -10 | N/A |
| 6/30/2019 | N/A | -23 | -9 | -9 | N/A |
| 3/31/2019 | N/A | -21 | -6 | -6 | N/A |
| 12/31/2018 | N/A | -12 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CABA * is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CABA * is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CABA * is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CABA * is forecast to have no revenue next year.
High Growth Revenue: CABA * is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CABA * is forecast to be unprofitable in 3 years.